Fulcrum Therapeutics (FULC) Earnings Date, Estimates & Call Transcripts → The Overlooked Retirement Asset You Probably Don’t Own (From Crypto 101 Media) (Ad) Free FULC Stock Alerts $7.98 +0.43 (+5.70%) (As of 08:36 AM ET) Add Compare Share Share EarningsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Earnings SummaryUpcoming Earnings DateAug. 1EstimatedActual EPS (Feb. 27) -$0.40 Beat By $0.04 Consensus EPS (Feb. 27) -$0.44 Get Fulcrum Therapeutics Earnings AlertsEnter your email address below to receive the latest news and earnings results for FULC and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueFULC Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.FULC Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Stansberry Research41 banks launch ‘crypto dollar’Everyone knows the US financial system is in the middle of a radical change... The White House wants an all-digital dollar. Plus at least 41 major banks (see if your bank is one of them right here).Here's how you capitalize (including #1 crypto to play it). Fulcrum Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20242($0.46)($0.40)($0.43)Q2 20242($0.43)$0.74$0.16Q3 20242($0.46)($0.43)($0.45)Q4 20242($0.45)($0.44)($0.45)FY 20248($1.80)($0.53)($1.17)FULC Earnings Date and InformationFulcrum Therapeutics last announced its earnings data on February 27th, 2024. The reported ($0.40) EPS for the quarter, topping analysts' consensus estimates of ($0.44) by $0.04. The company earned $0.87 million during the quarter, compared to analysts' expectations of $0.65 million. Fulcrum Therapeutics has generated ($1.60) earnings per share over the last year (($1.60) diluted earnings per share). Earnings for Fulcrum Therapeutics are expected to decrease in the coming year, from ($1.32) to ($1.71) per share. Fulcrum Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, August 1st, 2024 based off prior year's report dates.Read More Fulcrum Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript 8/1/2024Estimated)------- 2/27/2024Q4 2023($0.44)($0.40)+$0.04($0.40)$0.65 million$0.87 million11/7/2023Q3 2023($0.44)($0.39)+$0.05($0.39)$1.81 million$0.76 million8/3/2023Q2 2023($0.44)($0.38)+$0.06($0.38)$1.60 million$0.88 million5/15/2023Q1 2023($0.47)($0.41)+$0.06($0.41)$1.73 million$0.30 million3/9/2023Q4 2022($0.49)($0.50)($0.01)($0.50)$1.92 million$0.69 million11/8/2022Q3 2022($0.62)($0.50)+$0.12($0.49)$2.19 million$1.18 million Get the Latest News and Ratings for FULC and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Fulcrum Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 8/11/2022Q2 2022($0.66)($0.83)($0.17)($0.83)$2.65 million$1.88 million5/9/2022Q1 2022($0.63)($0.64)($0.01)($0.64)$3.46 million$2.59 million3/3/2022Q4 2021($0.65)($0.58)+$0.07($0.58)$4.00 million$5.06 million 11/4/2021Q3 2021($0.64)($0.57)+$0.07($0.57)$2.94 million$4.94 million 8/10/2021Q2 2021($0.65)($0.60)+$0.05($0.60)$2.69 million$4.38 million Fulcrum Therapeutics Earnings - Frequently Asked Questions When is Fulcrum Therapeutics's earnings date? Fulcrum Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, August 1st, 2024 based off last year's report dates. Learn more on FULC's earnings history. Did Fulcrum Therapeutics beat their earnings estimates last quarter? In the previous quarter, Fulcrum Therapeutics (NASDAQ:FULC) reported ($0.40) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.44) by $0.04. Learn more on analysts' earnings estimate vs. FULC's actual earnings. How much revenue does Fulcrum Therapeutics generate each year? Fulcrum Therapeutics (NASDAQ:FULC) has a recorded annual revenue of $2.81 million. How much profit does Fulcrum Therapeutics generate each year? Fulcrum Therapeutics (NASDAQ:FULC) has a recorded net income of -$97.33 million. FULC has generated -$1.60 earnings per share over the last four quarters. What is Fulcrum Therapeutics's EPS forecast for next year? Fulcrum Therapeutics's earnings are expected to decrease from ($1.32) per share to ($1.71) per share in the next year. More Earnings Resources from MarketBeat Related Companies: Entrada Therapeutics Earnings Theravance Biopharma Earnings Acelyrin Earnings Revance Therapeutics Earnings PepGen Earnings Esperion Therapeutics Earnings Neurogene Earnings Lexicon Pharmaceuticals Earnings Korro Bio Earnings Heron Therapeutics Earnings Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: Baidu Stock Earnings Prove Ray Dalio Right about China?JD’s Earnings Could Mean Chinese Stocks Making a ComebackHome Depot: Earnings Mixed, Wait to Buy the DipTraders Sell but Investors Still Win After Palantir's EarningsTech Earnings Insights: Where Opportunity Meets UncertaintyApple’s Earnings Show Investors Its Strength and Its WeaknessCarvana’s Q1 Earnings: A Profitability U-Turn This page (NASDAQ:FULC) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldUrgent Nvidia WarningAltimetryDoes this make you sick?Allegiance GoldThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarShocking: One AI startup's revenue could surge 4,735%Manward PressGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fulcrum Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.